Johnson Matthey Public Limited Company

Ptc Therapeutics, Inc.

Crinetics Pharmaceuticals, Inc.

Nektar Therapeutics

Agios Pharmaceuticals, Inc.

Kempharm, Inc.

Bioelectron Technology Corporation

Amag Pharmaceuticals, Inc.

Rxbio, Inc.

Mahmoud Mirmehrabi

Paul Mollard

Peter Giannousis

Shazad Suchit

Nicholas D Paschalides

Kieron E Wesson

Brian Heinrich

Christopher R Cornell

Jayachandra P Reddy

Aniruddh Singh

Patricia Andres

Daniel J Coughlin

Saroop Matharu

Charles Ryan Yates

Liting Guo

Karin Emmons Thompson

Da-Ming Gou

Veeresh Gududuru

Jacob P Sizemore

Ramakrishna Gadiraju

Bruce Andrew Kowalczyk

Gabriel Christian Kuklis

Rama Krishna Reddy Singidi

Yogesh Datar

Uttam Dash

Jurriaan Strobos

Madhukar Kota

Gabor Jozsef Tigyi

Yeqing Su

Rama Krishna Singidi

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency. 

Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Process of making somatostatin modulators

The disclosure is in part directed to crystalline forms of 17-&#x3b1;-hydroxyprogesterone caproate and variants thereof.

Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

An improved method for the preparation of the low ABUK oxymorphone hydrochloride is provided. The oxymorphone hydrochloride is produced by hydrogenating a starting material comprising oxymorphone base and 14-hydroxymorphinone in a mixture comprising an alcohol, water and an acid, removing some of the water and adding more alcohol to the mixture.

Process of preparing low ABUK oxymorphone hydrochloride

Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.

Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same

Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.

[object Object]

Here provided are a salt of Z)&#x2014;O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate with an L-lysine addition in crystalline form and methods of making and using the same.

Crystalline salts of (Z)-O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate

The present disclosure is directed to crystalline forms of morphine sulfate and pharmaceutical compositions comprising any of the crystalline forms of morphine sulfate. Also provided are processes for the preparation of crystalline forms of morphine sulfate.

Crystalline forms of morphine sulfate

The present disclosure is directed to crystalline forms of oxymorphone hydrochloride and compositions comprising any of the crystalline forms of oxymorphone hydrochloride. Also provided are processes for the preparation of crystalline forms of oxymorphone hydrochloride.

Forms of oxymorphone hydrochloride

Growing community of inventors

Halifax, Canada

Mahmoud Mirmehrabi